Last 12 months
Inside the activity.
0 purchase rows · 145 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 9 |
| Dec 2025 | 0 | 8 |
| Jan 2026 | 0 | 5 |
| Feb 2026 | 0 | 5 |
| Mar 2026 | 0 | 41 |
| Apr 2026 | 0 | 26 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 9 |
| Jul 2026 | 0 | 11 |
| Aug 2026 | 0 | 11 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 18 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 17, 2021 Filed Nov 19, 2021 21:59 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 3,700 | $32.05 | $118,585.00 |
DisclosureSEC source: 0001209191-21-065839 · doc4.xml · nonDerivative · entry 2 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,360 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $31.45 to 32.36, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 21:59 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionCommon Stock | 3,700 | $6.55 | $24,235.00 |
DisclosureSEC source: 0001209191-21-065839 · doc4.xml · nonDerivative · entry 1 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,060 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. Read SEC document |
| November 15, 2021 Filed Nov 18, 2021 01:00 UTC |
PISKEL KYLEPrincipal Accounting Officer
|
GrantStock Option (Right to Buy) · Derivative | 9,592 | $0.00 Strike: $32.58 | $0.00 |
DisclosureSEC source: 0001209191-21-065312 · doc4.xml · derivative · entry 2 PISKEL KYLE · CIK 0001780662 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,592 Underlying: Common Stock · 9,592 shares Expires 2031-11-15 F1 · derivative.exercise_date: The option will vest with respect to 1/4 of such shares on November 15, 2022, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| November 15, 2021 Filed Nov 18, 2021 01:00 UTC |
PISKEL KYLEPrincipal Accounting Officer
|
GrantCommon Stock | 3,837 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-065312 · doc4.xml · nonDerivative · entry 1 PISKEL KYLE · CIK 0001780662 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,699 Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 22:00 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001209191-21-064253 · doc4.xml · derivative · entry 6 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 5,000 shares Expires 2029-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on January 1, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 22:00 UTC |
Cohen Chad MChief Financial Officer
|
SaleCommon Stock | 5,000 | $33.93 | $169,650.00 |
DisclosureSEC source: 0001209191-21-064253 · doc4.xml · nonDerivative · entry 4 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,604 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $33.74 to 34.24, inclusive. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 22:00 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionCommon Stock | 5,000 | $7.27 | $36,350.00 |
DisclosureSEC source: 0001209191-21-064253 · doc4.xml · nonDerivative · entry 3 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 22:00 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001209191-21-064253 · doc4.xml · derivative · entry 5 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 5,000 shares Expires 2029-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on January 1, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 22:00 UTC |
Cohen Chad MChief Financial Officer
|
SaleCommon Stock | 5,000 | $36.03 | $180,150.00 |
DisclosureSEC source: 0001209191-21-064253 · doc4.xml · nonDerivative · entry 2 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,604 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $35.54 to 36.43, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 22:00 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionCommon Stock | 5,000 | $7.27 | $36,350.00 |
DisclosureSEC source: 0001209191-21-064253 · doc4.xml · nonDerivative · entry 1 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. Read SEC document |
| October 21, 2021 Filed Oct 22, 2021 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 3,700 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-061319 · doc4.xml · derivative · entry 10 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,800 Underlying: Common Stock · 3,700 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. F6 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| October 21, 2021 Filed Oct 22, 2021 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 3,700 | $33.73 | $124,801.00 |
DisclosureSEC source: 0001209191-21-061319 · doc4.xml · nonDerivative · entry 7 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,360 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $33.08 to 33.99, inclusive. Read SEC document |
| October 21, 2021 Filed Oct 22, 2021 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionCommon Stock | 3,700 | $6.55 | $24,235.00 |
DisclosureSEC source: 0001209191-21-061319 · doc4.xml · nonDerivative · entry 6 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,060 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. Read SEC document |
| October 20, 2021 Filed Oct 22, 2021 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 3,700 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-061319 · doc4.xml · derivative · entry 9 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,500 Underlying: Common Stock · 3,700 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. F6 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| October 20, 2021 Filed Oct 22, 2021 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 3,700 | $33.71 | $124,727.00 |
DisclosureSEC source: 0001209191-21-061319 · doc4.xml · nonDerivative · entry 5 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,360 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $33.08 to 34.01, inclusive. Read SEC document |
| October 20, 2021 Filed Oct 22, 2021 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionCommon Stock | 3,700 | $6.55 | $24,235.00 |
DisclosureSEC source: 0001209191-21-061319 · doc4.xml · nonDerivative · entry 4 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,060 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. Read SEC document |
| October 19, 2021 Filed Oct 22, 2021 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 3,800 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-061319 · doc4.xml · derivative · entry 8 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,200 Underlying: Common Stock · 3,800 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. F6 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| October 19, 2021 Filed Oct 22, 2021 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 3,500 | $33.76 | $118,160.00 |
DisclosureSEC source: 0001209191-21-061319 · doc4.xml · nonDerivative · entry 3 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,360 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $33.53 to 34.00, inclusive. Read SEC document |
| October 19, 2021 Filed Oct 22, 2021 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 300 | $32.91 | $9,873.00 |
DisclosureSEC source: 0001209191-21-061319 · doc4.xml · nonDerivative · entry 2 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,860 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $32.80 to 32.99, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| October 19, 2021 Filed Oct 22, 2021 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionCommon Stock | 3,800 | $6.55 | $24,890.00 |
DisclosureSEC source: 0001209191-21-061319 · doc4.xml · nonDerivative · entry 1 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,160 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. Read SEC document |
| October 08, 2021 Filed Oct 8, 2021 19:00 UTC |
ADAMS R MARKChief Operating Officer
|
SaleCommon Stock | 1,801 | $33.67 | $60,639.67 |
DisclosureSEC source: 0001209191-21-060116 · doc4.xml · nonDerivative · entry 2 ADAMS R MARK · CIK 0001808905 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,854 F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2021. Read SEC document |
| October 08, 2021 Filed Oct 8, 2021 23:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 3,895 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-060115 · doc4.xml · derivative · entry 10 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,110 Underlying: Common Stock · 3,895 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F6 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| October 08, 2021 Filed Oct 8, 2021 23:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 3,895 | $32.96 | $128,379.20 |
DisclosureSEC source: 0001209191-21-060115 · doc4.xml · nonDerivative · entry 7 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,360 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $32.68 to 33.33, inclusive. Read SEC document |
| October 08, 2021 Filed Oct 8, 2021 23:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionCommon Stock | 3,895 | $6.32 | $24,616.40 |
DisclosureSEC source: 0001209191-21-060115 · doc4.xml · nonDerivative · entry 6 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. Read SEC document |
| October 07, 2021 Filed Oct 8, 2021 19:00 UTC |
ADAMS R MARKChief Operating Officer
|
SaleCommon Stock | 1,324 | $32.47 | $42,990.28 |
DisclosureSEC source: 0001209191-21-060116 · doc4.xml · nonDerivative · entry 1 ADAMS R MARK · CIK 0001808905 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,655 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| October 07, 2021 Filed Oct 8, 2021 23:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 3,895 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-060115 · doc4.xml · derivative · entry 9 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,005 Underlying: Common Stock · 3,895 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F6 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| October 07, 2021 Filed Oct 8, 2021 23:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 3,695 | $33.68 | $124,447.60 |
DisclosureSEC source: 0001209191-21-060115 · doc4.xml · nonDerivative · entry 5 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,360 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $33.07 to 33.93, inclusive. Read SEC document |
| October 07, 2021 Filed Oct 8, 2021 23:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 200 | $32.50 | $6,500.00 |
DisclosureSEC source: 0001209191-21-060115 · doc4.xml · nonDerivative · entry 4 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,055 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $32.21 to 32.80, inclusive. Read SEC document |
| October 07, 2021 Filed Oct 8, 2021 23:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionCommon Stock | 3,895 | $6.32 | $24,616.40 |
DisclosureSEC source: 0001209191-21-060115 · doc4.xml · nonDerivative · entry 3 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. Read SEC document |
| October 06, 2021 Filed Oct 7, 2021 23:00 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001209191-21-059985 · doc4.xml · derivative · entry 6 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 5,000 shares Expires 2029-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on January 1, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| October 06, 2021 Filed Oct 7, 2021 23:00 UTC |
Cohen Chad MChief Financial Officer
|
SaleCommon Stock | 5,000 | $32.30 | $161,500.00 |
DisclosureSEC source: 0001209191-21-059985 · doc4.xml · nonDerivative · entry 4 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,604 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $32.01 to 32.59, inclusive. Read SEC document |
| October 06, 2021 Filed Oct 7, 2021 23:00 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionCommon Stock | 5,000 | $7.27 | $36,350.00 |
DisclosureSEC source: 0001209191-21-059985 · doc4.xml · nonDerivative · entry 3 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. Read SEC document |
| October 06, 2021 Filed Oct 8, 2021 23:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 3,895 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-060115 · doc4.xml · derivative · entry 8 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,900 Underlying: Common Stock · 3,895 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F6 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| October 06, 2021 Filed Oct 8, 2021 23:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 3,895 | $32.27 | $125,691.65 |
DisclosureSEC source: 0001209191-21-060115 · doc4.xml · nonDerivative · entry 2 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,360 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $31.82 to 32.78, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| October 06, 2021 Filed Oct 8, 2021 23:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionCommon Stock | 3,895 | $6.32 | $24,616.40 |
DisclosureSEC source: 0001209191-21-060115 · doc4.xml · nonDerivative · entry 1 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. Read SEC document |
| October 05, 2021 Filed Oct 7, 2021 23:00 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001209191-21-059985 · doc4.xml · derivative · entry 5 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 5,000 shares Expires 2029-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on January 1, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| October 05, 2021 Filed Oct 7, 2021 23:00 UTC |
Cohen Chad MChief Financial Officer
|
SaleCommon Stock | 5,000 | $32.51 | $162,550.00 |
DisclosureSEC source: 0001209191-21-059985 · doc4.xml · nonDerivative · entry 2 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,604 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $32.04 to 33.00, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| October 05, 2021 Filed Oct 7, 2021 23:00 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionCommon Stock | 5,000 | $7.27 | $36,350.00 |
DisclosureSEC source: 0001209191-21-059985 · doc4.xml · nonDerivative · entry 1 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. Read SEC document |
| September 15, 2021 Filed Sep 15, 2021 23:51 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 3,895 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-056261 · doc4.xml · derivative · entry 12 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,795 Underlying: Common Stock · 3,895 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F8 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| September 15, 2021 Filed Sep 15, 2021 23:51 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 900 | $37.23 | $33,507.00 |
DisclosureSEC source: 0001209191-21-056261 · doc4.xml · nonDerivative · entry 9 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,360 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F7 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $37.03 to 37.47, inclusive. Read SEC document |
| September 15, 2021 Filed Sep 15, 2021 23:51 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 2,995 | $36.52 | $109,377.40 |
DisclosureSEC source: 0001209191-21-056261 · doc4.xml · nonDerivative · entry 8 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,260 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F6 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $36.01 to 36.84, inclusive. Read SEC document |
| September 15, 2021 Filed Sep 15, 2021 23:51 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionCommon Stock | 3,895 | $6.32 | $24,616.40 |
DisclosureSEC source: 0001209191-21-056261 · doc4.xml · nonDerivative · entry 7 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. Read SEC document |
| September 14, 2021 Filed Sep 15, 2021 23:51 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 3,895 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-056261 · doc4.xml · derivative · entry 11 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,690 Underlying: Common Stock · 3,895 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F8 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| September 14, 2021 Filed Sep 15, 2021 23:51 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 1,100 | $37.36 | $41,096.00 |
DisclosureSEC source: 0001209191-21-056261 · doc4.xml · nonDerivative · entry 6 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,360 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $37.12 to 37.68, inclusive. Read SEC document |
| September 14, 2021 Filed Sep 15, 2021 23:51 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 2,795 | $36.49 | $101,989.55 |
DisclosureSEC source: 0001209191-21-056261 · doc4.xml · nonDerivative · entry 5 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,460 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $36.14 to 36.98, inclusive. Read SEC document |
| September 14, 2021 Filed Sep 15, 2021 23:51 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionCommon Stock | 3,895 | $6.32 | $24,616.40 |
DisclosureSEC source: 0001209191-21-056261 · doc4.xml · nonDerivative · entry 4 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 23:51 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 3,895 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-056261 · doc4.xml · derivative · entry 10 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,585 Underlying: Common Stock · 3,895 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F8 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 23:51 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 900 | $37.89 | $34,101.00 |
DisclosureSEC source: 0001209191-21-056261 · doc4.xml · nonDerivative · entry 3 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,360 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $37.72 to 38.10, inclusive. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 23:51 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 2,995 | $37.39 | $111,983.05 |
DisclosureSEC source: 0001209191-21-056261 · doc4.xml · nonDerivative · entry 2 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,260 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $36.72 to 37.68, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 23:51 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionCommon Stock | 3,895 | $6.32 | $24,616.40 |
DisclosureSEC source: 0001209191-21-056261 · doc4.xml · nonDerivative · entry 1 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.